reports
Emergent Biosolutions Inc: 4 directors
Four Directors at Emergent Biosolutions Inc sold 89,428 shares at 10.920USD. The significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Bavarian Nordic – afslutning af aktietilbagekøbsprogram
Bavarian Nordic – afslutning af aktietilbagekøbsprogram KØBENHAVN, Danmark, 9. februar 2026 – Bavarian Nordic A/S (OMX: BAVA) meddeler, at aktietilbagekøbsprogrammet, der blev offentliggjort og iværksat den 7. januar 2026, nu er afsluttet, da aktier til en samlet værdi af ca. DKK 150 mio. er tilbagekøbt som planlagt. Dette udgjorde den første del af et samlet planlagt aktietilbagekøb på op til DKK 500 mio. i løbet af 2026. Bavarian Nordic vil beholde de tilbagekøbte aktier som egne aktier med det formål at tilpasse kapitalstrukturen. Programmet blev gennemført i overensstemmelse med bestem...
Bavarian Nordic – Completion of Share Buy-Back Program
Bavarian Nordic – Completion of Share Buy-Back Program COPENHAGEN, Denmark, February 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 7, 2026, has now been completed, reaching an aggregate amount of approximately DKK 150 million as planned. This represented the first tranche of a total planned share buy-back of up to DKK 500 million in 2026. Bavarian Nordic will hold the shares bought back as treasury stock, for the purpose of adjusting the capital structure. The program was executed in accordance with Regulat...
Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprog...
Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram KØBENHAVN, Danmark, 2. februar 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggør transaktioner under aktietilbagekøbsprogrammet, der blev iværksat den 7. januar 2026, hvorunder selskaber vil tilbagekøbe aktier for op til DKK 150 mio. i perioden fra den 7. januar 2026 til den 13. februar 2026. Programmet gennemføres i overensstemmelse med bestemmelserne i Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 (ændret) om markedsmisbrug og den delegerede forordning (EU) nr. 2016/1052, der samlet udgør Safe Harbour...
Bavarian Nordic – Transactions in Connection with Share Buy-Back Progr...
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program COPENHAGEN, Denmark, February 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 7, 2026 to February 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute t...
Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprog...
Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram KØBENHAVN, Danmark, 26. januar 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggør transaktioner under aktietilbagekøbsprogrammet, der blev iværksat den 7. januar 2026, hvorunder selskaber vil tilbagekøbe aktier for op til DKK 150 mio. i perioden fra den 7. januar 2026 til den 13. februar 2026. Programmet gennemføres i overensstemmelse med bestemmelserne i Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 (ændret) om markedsmisbrug og den delegerede forordning (EU) nr. 2016/1052, der samlet udgør Safe Harbour...
Bavarian Nordic – Transactions in Connection with Share Buy-Back Progr...
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program COPENHAGEN, Denmark, January 26, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 7, 2026 to February 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute t...
Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprog...
Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram KØBENHAVN, Danmark, 19. januar 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggør transaktioner under aktietilbagekøbsprogrammet, der blev iværksat den 7. januar 2026, hvorunder selskaber vil tilbagekøbe aktier for op til DKK 150 mio. i perioden fra den 7. januar 2026 til den 13. februar 2026. Programmet gennemføres i overensstemmelse med bestemmelserne i Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 (ændret) om markedsmisbrug og den delegerede forordning (EU) nr. 2016/1052, der samlet udgør Safe Harbour...
Bavarian Nordic – Transactions in Connection with Share Buy-Back Progr...
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program COPENHAGEN, Denmark, January 19, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 7, 2026 to February 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute th...
Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New D...
Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness Since the U.S. prescription launch of NARCAN® Nasal Spray in 2016, the medicine has been trusted as a safe, effective way to reverse opioid overdoses, and today, new solutions like the NARCAN® carrying case aims to make accessibility paramount - ‘Trusted Then. Trusted Now’ GAITHERSBURG, Md., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions announced that the ...
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Prin...
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions, Inc. (NYSE: EBS) announced it made a voluntary prepayment of $100 million under its outstanding term loan facility in late December 2025 using cash on hand. “This significant milestone reflects strong progress in improving our overall financial/cash position, enhancing our financial flexibility and positioning Emergent for long-term stability and growth,” stated Joe P...
Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprog...
Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram KØBENHAVN, Danmark, 12. januar 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggør transaktioner under aktietilbagekøbsprogrammet, der blev iværksat den 7. januar 2026, hvorunder selskabet vil tilbagekøbe aktier for op til DKK 150 mio. i perioden fra den 7. januar 2026 til den 13. februar 2026. Programmet gennemføres i overensstemmelse med bestemmelserne i Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 (ændret) om markedsmisbrug og den delegerede forordning (EU) nr. 2016/1052, der samlet udgør Safe Harbour...
Bavarian Nordic – Transactions in Connection with Share Buy-Back Progr...
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program COPENHAGEN, Denmark, January 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 7, 2026 to February 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute th...
Emergent BioSolutions Receives Delivery Order up to $21.5 Million to S...
Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026 GAITHERSBURG, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced it has received a delivery order valued at up to $21.5 million from the U.S. Department of War to supply BioThrax® (Anthrax Vaccine Adsorbed) in 2026. This order is under Emergent’s (W911SR24D0001), led by the Capability Program Executive Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND), previously the Joint Program Exec...
Emergent BioSolutions and PANTHER Announce Agreement to Support the Co...
Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa GAITHERSBURG, Md. and PARIS and ADDIS ABABA, Ethiopia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced a collaboration agreement with PANTHER to provide additional financial support to continue progressing the Africa CDC-led ‘MpOx Study in Africa’ (MOSA). This initiative aims to advance research into effective treatments for patients diagnosed with mpox, a virus for which there is currently no dedicated antiviral therapy. Launched ...
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Health...
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 GAITHERSBURG, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that Joe Papa, president and chief executive officer, will provide a company presentation during the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 5:15 PM PST. The audio link for Emergent’s session may be accessed and will be live for up to 30 days. The Company’s slides will be made available at the time of the presentation on the of the Eme...
Bavarian Nordic lancerer planlagt aktietilbagekøbsprogram
Bavarian Nordic lancerer planlagt aktietilbagekøbsprogram KØBENHAVN, Danmark, 7. januar 2026 – Bavarian Nordic A/S (OMX: BAVA) iværksætter nu den første del af aktietilbagekøbsprogrammet, som blev , hvorunder selskabet vil tilbagekøbe egne aktier for op til DKK 500 mio. i løbet af 2026. Den første del vil omfatte tilbagekøb af aktier for op til DKK 150 mio., som selskabet vil beholde som egne aktier med det formål at tilpasse kapitalstrukturen. Aktietilbagekøbsprogrammet iværksættes i henhold til generalforsamlingens bemyndigelse af 9. april 2025 samt i overensstemmelse med bestemmelserne...
Bavarian Nordic Launches Planned Share Buy-Back Program
Bavarian Nordic Launches Planned Share Buy-Back Program COPENHAGEN, Denmark, January 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the first tranche of the share buy-back program , under which the Company intends to repurchase own shares for up to DKK 500 million during 2026. The first tranche will comprise buy-back of shares for up to DKK 150 million, which will be held as treasury stock for the purpose of adjusting the capital structure. The share buy-back program is initiated pursuant to the authorization granted at the annual general meeting on April 9, 2025, and in accord...
Bavarian Nordic iværksætter nyt langsigtet incitamentsprogram for konc...
Bavarian Nordic iværksætter nyt langsigtet incitamentsprogram for koncernledelsen og udvalgte medarbejdere KØBENHAVN, Danmark, 18. december 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at bestyrelsen har besluttet at etablere et nyt langsigtet incitamentsprogram for koncernledelsen som en del af den årlige aflønning i overensstemmelse med vederlagspolitikken, som er vedtaget på generalforsamlingen. Medlemmer af koncernledelsen tildeles performancebaserede betingede aktier, der er baseret på succesfuld opnåelse af relevante Key Performance Indicators (KPI’er), målt over en treårig...
Bavarian Nordic Establishes Long-term Incentive Program for Members of...
Bavarian Nordic Establishes Long-term Incentive Program for Members of Executive Management and Selected Employees COPENHAGEN, Denmark, December 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a long-term incentive program for Executive Management as part of the annual remuneration as laid out in the Remuneration Policy, adopted at the annual general meeting. Members of the Executive Management are granted performance restricted stock units (Performance RSUs), subject to the successful achievement of relevant Key Performance In...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.